BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hassib ST, Taha EA, Elkady EF, Barakat GH. Reversed-Phase Liquid Chromatographic Method for Determination of Daclatasvir Dihydrochloride and Study of Its Degradation Behavior. Chromatographia 2017;80:1101-7. [DOI: 10.1007/s10337-017-3321-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Zaman B, Hassan W. Development of Stability Indicating HPLC–UV Method for Determination of Daclatasvir and Characterization of Forced Degradation Products. Chromatographia 2018;81:785-97. [DOI: 10.1007/s10337-018-3503-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
2 Abdallah OM, Abdel-megied AM, Gouda AS. Pharmacokinetic evaluation of daclatasvir and ledipasvir in healthy volunteers using a validated highly sensitive spectrofluorimetric method. Luminescence 2018;33:1094-100. [DOI: 10.1002/bio.3514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Joghani RA, Rafati AA, Ghodsi J, Assari P, Feizollahi A. A sensitive voltammetric sensor based on carbon nanotube/nickel nanoparticle for determination of daclatasvir (an anti-hepatitis C drug) in real samples. J Appl Electrochem 2020;50:1199-208. [DOI: 10.1007/s10800-020-01478-1] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Youssef AA, Magdy N, Hussein LA, El-Kosasy AM. Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt. J Chromatogr Sci 2019;57:636-43. [PMID: 31063182 DOI: 10.1093/chromsci/bmz038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
5 Abdel-lateef MA, Omar MA, Ali R, Derayea SM. Micellar spectrofluorimetric protocol for the innovative determination of HCV antiviral (daclatasvir) with enhanced sensitivity: Application to human plasma and stability study. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2019;206:57-64. [DOI: 10.1016/j.saa.2018.07.101] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 5.7] [Reference Citation Analysis]
6 Abdallah IA, Hammad SF, Bedair A, Mansour FR. A green homogeneous liquid-liquid microextraction method for spectrophotometric determination of daclatasvir in human plasma. Sustainable Chemistry and Pharmacy 2021;22:100498. [DOI: 10.1016/j.scp.2021.100498] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Naz A, Sher N, Siddiqui FA, Kashif M, Ansari A. Simultaneous analysis of daclatasvir with its three organic impurities: Application in stability studies, pharmaceuticals and serum samples. Microchemical Journal 2019;147:797-805. [DOI: 10.1016/j.microc.2019.03.045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ibrahim AE, Hashem H, Elhenawee M, Saleh H. Comparison between core-shell and totally porous particle stationary phases for fast and green LC determination of five hepatitis-C antiviral drugs. J Sep Sci 2018;41:1734-42. [PMID: 29297968 DOI: 10.1002/jssc.201701263] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
9 Almahri A, Abdel-Lateef MA. Applying different spectroscopic techniques for the selective determination of daclatasvir using merbromin as a probe: Applications on pharmaceutical analysis. Luminescence 2021;36:1544-52. [PMID: 34080773 DOI: 10.1002/bio.4099] [Reference Citation Analysis]
10 Abdel Ghani NT, Abdulla H, Rizk MS, Dena ASA, El Nashar RM. Molecularly imprinted polymer/reduced graphene oxide‒based carbon‒paste sensor for highly sensitive determination of the anti‒HCV drug daclatasvir dihydrochloride. Sensors and Actuators B: Chemical 2019;283:6-17. [DOI: 10.1016/j.snb.2018.11.158] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
11 Abdallah OM, Abdel-Megied AM, Gouda AS. Development and validation of LC-MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: Application to pharmacokinetic study. Biomed Chromatogr 2018;32:e4186. [PMID: 29314090 DOI: 10.1002/bmc.4186] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]